| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2015 | WO2015001436A1 Alkoxyamines for the treatment of cancers |
| 01/08/2015 | WO2015001379A1 Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders |
| 01/08/2015 | WO2015001359A1 Drug combination and its use in therapy of obesity |
| 01/08/2015 | WO2015001358A1 Drug combination and its use in therapy of obesity and type ii diabetes |
| 01/08/2015 | WO2015001357A2 Drug combination and its use in therapy |
| 01/08/2015 | WO2015001349A1 Methods and compounds for preventing osteoarthritis |
| 01/08/2015 | WO2015001348A1 Pyridazine derivatives as hedgehog pathway inhibitors |
| 01/08/2015 | WO2015001175A1 Edible composition suitable for lowering serum cholesterol |
| 01/08/2015 | WO2015001133A1 Pharmaceutical composition comprising amorphous ivabradine |
| 01/08/2015 | WO2015001125A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| 01/08/2015 | WO2015001099A1 Varenicline and/or topiramate for use in the treatment of behavioral disorders and/or angina pectoris |
| 01/08/2015 | WO2015001098A1 Crystalline forms of ponatinib hydrochloride |
| 01/08/2015 | WO2015001076A1 Novel gak modulators |
| 01/08/2015 | WO2015001024A1 2-acylaminothiazoles for the treatment of cancer |
| 01/08/2015 | WO2015001021A1 Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
| 01/08/2015 | WO2015000986A1 Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases |
| 01/08/2015 | WO2015000961A1 Use of an isopropanol-containing solution to combat calciviridae |
| 01/08/2015 | WO2015000959A1 4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase |
| 01/08/2015 | WO2015000949A1 Heteroaryl pyridone and aza-pyridone amide compounds |
| 01/08/2015 | WO2015000929A1 N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-(trifluoromethylsulfanyl)benzamide derivatives for use as nematocidal drugs |
| 01/08/2015 | WO2015000921A1 Ptgds pathway activators and use in pathologies characterized by altered myelination in the cns |
| 01/08/2015 | WO2015000868A1 Novel compounds |
| 01/08/2015 | WO2015000867A1 Benzothiophene derivatives as estrogen receptor inhibitors |
| 01/08/2015 | WO2015000833A1 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| 01/08/2015 | WO2015000825A1 Compounds with antibacterial activity |
| 01/08/2015 | WO2015000800A1 Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord motor disorders |
| 01/08/2015 | WO2015000694A1 Lactoferrin-osteopontin-iron complex |
| 01/08/2015 | WO2015000431A1 Tizoxanide carbamate and pharmaceutical use thereof |
| 01/08/2015 | WO2015000412A1 Benzocyclobutene derivative and preparation method and pharmaceutical application thereof |
| 01/08/2015 | WO2015000411A1 Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof |
| 01/08/2015 | WO2015000370A1 Pyrroloquinoline quinone lithium salt crystal and preparation method and application thereof |
| 01/08/2015 | WO2015000174A1 Joint health compositions |
| 01/08/2015 | WO2015000064A1 Composition for treating pain and/or inflammation comprising eugenol and beta-caryophyllene |
| 01/08/2015 | WO2015000035A1 Method for preventing and/or treating chronic traumatic encephalopathy-iv |
| 01/08/2015 | WO2015000034A1 Method for preventing and/or treating chronic traumatic encephalopathy-iii |
| 01/08/2015 | WO2015000033A1 Method for preventing and/or treating chronic traumatic encephalopathy-ii |
| 01/08/2015 | WO2015000032A1 Method for preventing and/or treating chronic traumatic encephalopathy-i |
| 01/08/2015 | WO2015000022A1 Treatment and prevention of mastitis |
| 01/08/2015 | WO2014153226A9 Arginine methyltransferase inhibitors and uses thereof |
| 01/08/2015 | WO2014099788A9 C5-spiro iminothiadiazine dioxides as bace inhibitors |
| 01/08/2015 | WO2013169979A9 Polymorph compositions, methods of making, and uses thereof |
| 01/08/2015 | WO2013156871A9 Thromboxane receptor antagonists |
| 01/08/2015 | US20150011776 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
| 01/08/2015 | US20150011767 Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints |
| 01/08/2015 | US20150011736 Binding molecule conjugates |
| 01/08/2015 | US20150011655 Flow system method for preparing substantially pure nanoparticles, nanoparticles obtained by this method and use thereof |
| 01/08/2015 | US20150011653 Novel Microbial Pathogen inhibitor |
| 01/08/2015 | US20150011651 Alcoholic compositions having a lowered risk of acetaldehydemia |
| 01/08/2015 | US20150011650 Method for treating non-melanoma skin cancer by inducing udp-glucuronosyltransferase activity using pterostilbene |
| 01/08/2015 | US20150011649 Methods of treating infectious diseases |
| 01/08/2015 | US20150011648 Process for the maintaining of a ratio of isomers of carotenoid compounds |
| 01/08/2015 | US20150011646 Usage of guttiferone k, a natural compound from garcinia yunnanensis hu on treating high metastatic esophageal cancer |
| 01/08/2015 | US20150011644 Methods and Compositions for Deterring Abuse |
| 01/08/2015 | US20150011643 Treatment of heart failure and associated conditions by administration of monoamine oxidase inhibitors |
| 01/08/2015 | US20150011641 High load dispersions |
| 01/08/2015 | US20150011640 Gynecologic composition to treat vulvar vestibulitis |
| 01/08/2015 | US20150011638 Alprostadil and lidocaine treatment of premature ejaculation |
| 01/08/2015 | US20150011635 Diclofenac topical formulation |
| 01/08/2015 | US20150011634 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| 01/08/2015 | US20150011633 Pharmaceutical formulations containing lipoic acid derivatives |
| 01/08/2015 | US20150011631 Cetylated fatty acid and alkali buffered creative anti-inflammatory composition |
| 01/08/2015 | US20150011630 Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
| 01/08/2015 | US20150011626 Methods of treating and preventing diseases and disorders of the central nervous system |
| 01/08/2015 | US20150011624 Method for extracting treatment ingredients for gastrointestinal diseases from bark of liriodendron tulipifera |
| 01/08/2015 | US20150011623 Pharmaceutical Composition Containing as Active Ingredient Extract From Bark of Liriodendron Tulipifera |
| 01/08/2015 | US20150011622 Dosage Form Containing Extract From Bark of Liriodendron Tulipifera as Active Ingredient |
| 01/08/2015 | US20150011617 Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases |
| 01/08/2015 | US20150011615 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides |
| 01/08/2015 | US20150011612 RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF |
| 01/08/2015 | US20150011611 Inhibition of the glycine cleavage system for treatment of cancer |
| 01/08/2015 | US20150011610 Method for enhancing remyelination using gli1 inhibitors |
| 01/08/2015 | US20150011608 iRNA Agents Targeting VEGF |
| 01/08/2015 | US20150011602 Stabilized pharmaceutical dosage forms comprising atrasentan |
| 01/08/2015 | US20150011601 Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
| 01/08/2015 | US20150011598 Pharmaceutical composition comprising candesartan or ester thereof and chlortalidone, and use thereof |
| 01/08/2015 | US20150011596 Topical localized isoxazoline formulation comprising glycofurol |
| 01/08/2015 | US20150011595 Inhibitors of Cholesterol Ester Transfer Protein |
| 01/08/2015 | US20150011594 Bin1 expression as a marker of cancer |
| 01/08/2015 | US20150011593 Artificial skin |
| 01/08/2015 | US20150011590 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 01/08/2015 | US20150011588 Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 01/08/2015 | US20150011587 Alprostadil for treatment of premature ejaculation |
| 01/08/2015 | US20150011585 Alprostadil and dyclonine for treatment of premature ejaculation |
| 01/08/2015 | US20150011584 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors |
| 01/08/2015 | US20150011581 Treatment of progressive neurodegenerative disease with ibudilast |
| 01/08/2015 | US20150011578 Methods for improving muscle strength |
| 01/08/2015 | US20150011577 Oxymorphone controlled release formulations |
| 01/08/2015 | US20150011571 Valaciclovir and celecoxib combination therapy for functional somatic syndromes |
| 01/08/2015 | US20150011570 Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| 01/08/2015 | US20150011569 NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF |
| 01/08/2015 | US20150011568 Famciclovir for the Treatment of Recurrent Herpes Labialis Using a One-Day Treatment |
| 01/08/2015 | US20150011566 N-phenylpiperazine derivatives that are antagonists of a1a, a1d adrenoceptors and 5-ht1a receptors for the treatment of benign prostate hyperplasia, pharmaceutical compositions containing the same |
| 01/08/2015 | US20150011563 Treating Sexual Desire Disorders with Flibanserin |
| 01/08/2015 | US20150011562 Benzamide derivatives as modulators of the follicle stimulating hormone |
| 01/08/2015 | US20150011561 Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor |
| 01/08/2015 | US20150011560 Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| 01/08/2015 | US20150011557 Benzyl Piperidine Compounds as Lysophosphatidic Acid (LPA) Receptor Antagonist |
| 01/08/2015 | US20150011554 Compositions and Methods for Treating Metabolic Disorders |
| 01/08/2015 | US20150011550 Methods for treating alzheimer's disease by administering certain synthetic compounds |
| 01/08/2015 | US20150011542 Methods of Treating Adverse Intestinal Effects of Non-Steroidal Anti-Inflammatory Drugs |